EUROIMMUN AG

What EUROIMMUN AG does

EUROIMMUN Medizinische Labordiagnostika AG is a German medical laboratory diagnostics manufacturer founded in 1987 and headquartered in Lübeck, Germany. The company develops, manufactures, and distributes diagnostic test systems, reagents, and automation instruments used by medical laboratories worldwide. Its product portfolio is organized around seven disease areas—autoimmunity, infectious diseases, allergy, endocrinology, bone metabolism, neurodegeneration, and therapeutic drug monitoring—supported by seven detection techniques including Indirect Immunofluorescence (IIFT), ELISA, Chemiluminescence Immunoassay (ChLIA), Immunoblot, microarray (EUROArray), real-time PCR (EURORealTime), and Dried Blood Spots (DBS). Automation platforms include the UNIQO160 all-in-one IFA device, the IDS i20 random access ChLIA analyzer, and the EUROLabLiquidHandler.

EUROIMMUN sells to clinical diagnostic laboratories globally through direct subsidiaries in 17 countries (Germany, France, Italy, Poland, Portugal, Spain, Switzerland, Turkey, the UK, the US, Canada, Mexico, Brazil, China, Japan, Singapore, and South Africa) supplemented by a network of local distribution partners. The company is a wholly owned subsidiary of Revvity, Inc., and operates Immunodiagnostic Systems (IDS) as an integrated subsidiary, with both entities consolidating IT and email systems. In 2025, EUROIMMUN received the first FDA 510(k) clearance for an automated chemiluminescence immunoassay measuring free testosterone, marking a US regulatory milestone.

The business model is B2B sale of diagnostic reagents, kits, consumables, and instrumentation to medical laboratories, with quote-based pricing and no publicly disclosed list prices. The company employs more than 3,500 people across 17 countries and is led by Chairman of the Executive Board Dirk Beecker, with Executive Board members Dr. Bianca Huth and Dr. Lars Komorowski, and Chairman of the Supervisory Board Dr. Wolfgang Schlumberger.

Name

EUROIMMUN AG

Legal name

EUROIMMUN Medizinische Labordiagnostika AG

Website

https://euroimmun.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

EUROIMMUN AG is a German medical laboratory diagnostics manufacturer serving clinical laboratories worldwide with immunoassay, molecular diagnostic, and automation products spanning autoimmunity, infectious diseases, allergy, endocrinology, bone metabolism, neurodegeneration, and therapeutic drug monitoring. Operates as a wholly owned subsidiary of Revvity, Inc.

Ownership category

akta.pro rank

Headquarters

HQ city

Lübeck

HQ country

Germany

HQ region

Europe

Offices17 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Diagnostic Products: Sale of medical diagnostic products including reagents, test kits, and consumables for laboratory diagnostics.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

EUROIMMUN AG develops and manufactures medical laboratory diagnostic products, including reagents, test kits and automation devices, for clinical laboratories worldwide. Its portfolio spans disease areas such as autoimmunity, infectious diseases, allergy, endocrinology, bone metabolism, neurodegeneration and therapeutic drug monitoring, supported by proprietary automation platforms such as the UNIQO160 IFA device and the IDS i20 random access chemiluminescence analyzer.

Product overview

EUROIMMUN AG is a leading manufacturer of medical diagnostic products for laboratory diagnostics in human medicine. The company operates as part of Revvity, Inc. and offers a comprehensive portfolio organized around diagnostic disease areas (Autoimmunity, Infectious Diseases, Allergy, Endocrinology, Bone Metabolism, Neurodegeneration, Therapeutic Drug Monitoring) and Research Parameters. The core offerings span multiple detection techniques including IIFT (Indirect Immunofluorescence), ELISA, ChLIA (Chemiluminescence Immunoassay), Immunoblot (EUROLINE/MICROBLOT), EUROArray (microarray), EURORealTime (PCR), and Dried Blood Spots. Automation solutions include the UNIQO160 all-in-one IFA device and the IDS i20 random access ChLIA analyzer. The company maintains subsidiaries in 17 countries and distributes products globally through direct offices and local representatives.

Differentiator

Problem solved

Functional benefit

Brands

• Immunodiagnostic Systems (IDS): Diagnostic assays and instrumentation portfolio, now part of Euroimmun family.

Products and services

• Autoimmunity Diagnostics Diagnostic test portfolio for autoimmune diseases covering rheumatology, hepatology, gastroenterology, neurology, nephrology and dermatology, sold to clinical laboratories.
• Infectious Diseases Diagnostics Diagnostic tests for infectious diseases including gastrointestinal, respiratory, CSF, parasite, pregnancy-relevant, sexually transmitted, tick-borne, emerging, herpes virus and mycoses infections, as well as vaccine-preventable diseases.
• Allergy Diagnostics Allergy testing products including Total IgE and specific allergen panels for identifying allergic sensitivities in clinical laboratory settings.
• Endocrinology Diagnostics Tests for endocrine disorders including diabetology, thyroidology, hypertension, growth disorders, adrenal function and reproductive health. Includes the FDA 510(k)-cleared automated free testosterone chemiluminescence immunoassay.
• Bone Metabolism Diagnostics Tests for bone-related conditions including cartilage destruction, bone turnover disorders, CKD-MBD and vitamin D deficiency.
• Neurodegeneration Diagnostics Tests for neurodegenerative diseases including Alzheimer's disease and amyotrophic lateral sclerosis (ALS), leveraging the UNIQO160 device and cell-based assay portfolio.
• Therapeutic Drug Monitoring (TDM) Drug monitoring tests including TDM in inflammatory diseases to support personalized medicine and optimized treatment.
• Research Parameters Research-use-only tests for autoimmunity, infections and neurodegeneration research applications.
• UNIQO160 IFA Automation Device All-in-one indirect immunofluorescence automation device featuring a unique cell-based assay (CBA) portfolio for neurological diagnostics, with fluorescence reading capabilities.
• IDS i20 Random Access ChLIA Analyzer Random access chemiluminescence immunoassay (ChLIA) automation device designed for reliability, versatility and usability, enabling efficient, flexible and simple automation of ChLIA tests.
• EUROLabLiquidHandler Automated liquid handling system for ELISA processing in clinical laboratories.

Named customers1 record

Segments7 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Immunodiagnostic Systems (IDS)coreStrategic or Co-development PartnerIDS (Immunodiagnostic Systems) is a strategic partner. Joint development has produced products like the IDS i20 random access analyzer. Euroimmun and IDS work together on automation solutions. Email consolidation has been implemented for all Euroimmun and IDS employees.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Werfen (INOVA Diagnostics): Werfen owns INOVA Diagnostics, a leading specialty IVD company focused on autoimmune diagnostics. INOVA competes head-to-head with EUROIMMUN in autoantibody testing (e.g., ANA, anti-dsDNA, celiac) using similar IIFT, ELISA, and immunoblot technologies, targeting the same clinical laboratory customers globally.
• Bio-Rad Laboratories: Bio-Rad's Clinical Diagnostics division offers autoimmune and infectious disease immunoassays (including the BioPlex 2200 system), directly competing with EUROIMMUN in specialty clinical laboratories. Bio-Rad is one of the most direct comparables in autoimmune multiplex testing.
• DiaSorin: Italian specialty IVD company with strong positions in infectious disease serology, autoimmune diagnostics, and vitamin D/endocrine testing. DiaSorin competes with EUROIMMUN in similar specialty niches with overlapping CLIA and ELISA technology platforms.

Broad incumbents

• Thermo Fisher Scientific (Clinical Diagnostics): Through its Specialty Diagnostics segment and platforms like Phadia (allergy), EliA (autoimmune), and ImmunoCAP, Thermo Fisher competes with EUROIMMUN across allergy, autoimmune, and infectious disease testing. It is a much broader life sciences incumbent with overlapping but not directly identical specialty offerings.
• Revvity (formerly PerkinElmer): Parent company of EUROIMMUN. Revvity's broader clinical diagnostics and life sciences portfolio overlaps with EUROIMMUN's offerings (newborn screening, reproductive health, applied genomics) and provides the corporate platform from which EUROIMMUN operates.
• Roche Diagnostics: Global IVD market leader with cobas and Elecsys platforms spanning immunoassay, clinical chemistry, and molecular diagnostics. While Roche dominates high-throughput routine testing, it also competes with EUROIMMUN in specialty autoimmune, infectious disease, and endocrinology test menus.
• Abbott Diagnostics: Major IVD player with Architect and Alinity immunoassay platforms covering autoimmune, infectious disease, and endocrine testing. Abbott competes broadly with EUROIMMUN in clinical laboratories globally.
• Siemens Healthineers: Operates the Atellica and ADVIA Centaur immunoassay systems with broad specialty menus including infectious disease and endocrinology. Siemens competes with EUROIMMUN for routine and specialty lab testing contracts.
• Beckman Coulter (Danaher): Danaher's clinical diagnostics arm offers Access and DxH immunoassay systems. Beckman Coulter competes with EUROIMMUN in clinical chemistry, immunoassay, and specialty testing for hospital and reference lab customers.
• Hologic: Diagnostic specialist with strong positions in molecular diagnostics, women's health, and infectious disease testing (Panther, Aptima, Biotheranostics). Hologic competes with EUROIMMUN in infectious disease and is a leader in molecular testing where EUROIMMUN is expanding.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/euroimmun
• YouTubeyoutube.com/user/EUROIMMUN
• Facebookfacebook.com/Euroimmun
• LinkedInlinkedin.com/company/euroimmunturkey
• Instagraminstagram.com/euroimmun

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EUROIMMUN AG